US covid cases show tentative signs of flattening, could help investors see glass half-full

US COVID-19 cases are showing tentative signs of flattening in the current winter wave.
Markets are torn between promising vaccine news and grim reality.
Signs of stability could help focus investors on the upbeat scenario.

Light at the end of the tunnel – Pfizer and BioNTech reported 95% efficacy in their coronavirus candidate, better than 90% initially reporting and topping rivals Moderna. The joint venture is set to ask authorization to begin inoculating the public shortly.

The cavalry – from these two efforts and others such as AstraZeneca and Johnson & Johnson – is on its way. However, production, storage, and distribution challenges mean a long road to the end of that tunnel. After the initial shot in the arm, markets looked back at grim reality.

COVID-19 cases continue rising in the northern hemisphere, hitting Europe, the US, and even Japan. Governors in various American states have begun introducing restrictions, following governments and regions in the old continent. The potential damage to economic activity – both from lockdowns and from consumer caution – is of concern.

Fear of "scarring" – long-term damage to the economy, are in play. In the US, lawmakers have yet to agree on a new fiscal relief package, leaving investors at the mercy of the virus development. Finally, there are some tentative signs that the surge seen from mid-October is hitting a standstill.

A daily average of around 160,000 cases is still worrisome and implies hospitals and mortalities – which lag infections – are set to rise. Moreover, as every technical trader knows, this may be a mere consolidation of the uptrend rather than a change of course.

Nevertheless, a pause is better than an extension of an uptrend. Also, measures already implemented by various states could still push the curve down.

Seeing the chart above could encourage investors to see the glass as half full than half empty.

See What you need to know about the dollar in the post-vaccine announcement world

Share: Analysis feed

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.